Glaxo’s start of Phase 1 study of HBV drug triggers $1.5M milestone to Ionis Pharma
Ionis Pharmaceuticals (NASDAQ:IONS) earns a $1.5M milestone payment from development partner GlaxoSmithKline (NYSE:GSK) triggered by the latter’s initiation of a Phase 1 clinical trial assessing IONIS-HBV-Lrx for the treatment of hepatitis B virus (HBV) infection. The drug candidate incorporates Ionis’ Ligand Conjugated Antisense (LICA) technology which increases drug potency by enhancing its delivery to target tissue, in this case, the liver.
Share This Page
Follow Us
Comments
Glaxo’s start of Phase 1 study of HBV drug triggers $1.5M milestone to Ionis Pharma — No Comments